Who Invented Nootropics? The 1972 Origin Story of Giurgea, Piracetam, and a New Word

Who Invented Nootropics? The 1972 Origin Story of Giurgea, Piracetam, and a New Word

The question of who invented nootropics has a precise answer: a Romanian-born psychologist and chemist named Corneliu Giurgea, working in Belgium in 1972. He did not just discover a molecule. He invented a word and, with it, an entire category of science.

Most categories in pharmacology get named after the fact. This one arrived with a definition first, a strict five-part test that a compound had to pass before earning the label. That test still matters today, and most products sold as "smart drugs" would fail it.

Here is how a single researcher gave the world both the first nootropic and the rules for what counts as one.

Key Takeaways

• The term "nootropic" was coined in 1972 by Corneliu Giurgea, a researcher at the Belgian pharmaceutical company UCB.
• The first nootropic was piracetam, synthesized at UCB around 1964 and later sold in Europe as Nootropil.
• Giurgea built the nootropic definition around five criteria, with low toxicity and few side effects as a hard requirement.
• The word comes from Greek roots meaning, roughly, "toward the mind."
• Giurgea's original standard, high benefit paired with low harm, still separates real cognitive compounds from hype.

Who Invented Nootropics? Corneliu Giurgea and the Word He Built

The person who invented nootropics, in the sense of naming and defining them, was Corneliu Giurgea. He was a pharmacologist trained in the tradition of Russian physiologist Ivan Pavlov, and he spent much of his career at UCB Pharma in Belgium.

Giurgea introduced the term in a 1972 paper. According to the biography compiled by Noomind, in 1972, Giurgea introduced the term "nootropic" to describe this new category of cognitive enhancers. The paper itself carried a dense academic title about the pharmacology of the brain's integrative activity.

What made the move unusual was the order of operations. Giurgea already had the compound. What he lacked was a name for what it did, because it did not behave like any drug class that existed.

Where the Word Comes From

The name is Greek. The "noo" piece points to the mind, and the "trop" piece points to a turning or directing action.

There is a long-running dispute about the exact translation. The site Nootroo argues, citing Giurgea's own writing, that the word "nootropic" comes from the Greek word "noos" meaning "mind" and "tropein" meaning "towards" and was coined in 1972 by Corneliu Giurgea to describe a class of compounds that selectively act "towards the mind." Other sources translate the suffix as "to bend or turn." Either way, the intent is the same: a substance aimed at cognition itself, not at mood or sedation.

That distinction is the whole point. Giurgea was drawing a line between drugs that act on the mind and drugs that act toward it.

The First Nootropic: Piracetam and an Accidental Discovery

Piracetam was the first nootropic, and it arrived years before the word that described it. The history of nootropics really starts in a UCB lab in the mid-1960s, not in 1972.

According to Nootropics Expert, Piracetam was first synthesized by Dr. Corneliu Giurgea at Belgian-based pharmaceutical company UCB Pharma in the 1964. The compound is a cyclic derivative of GABA, the brain's main calming neurotransmitter.

Here is where it gets interesting. Piracetam is considered the first true nootropic ever developed. As a cyclic derivative of GABA, the drug Piracetam was first intended to be a calming type of drug for motion sickness. But in spite of its connection with GABA, Piracetam didn't show any behavior associated with this calming neurotransmitter. And cannot directly affect GABA receptors.

The drug refused to do its assigned job. Instead of calming people down, it appeared to sharpen them.

From Motion Sickness to Memory

When the sedative idea failed, Giurgea noticed something more interesting in its place. Dr. Giurgea discovered that Piracetam was able to boost cognition even in healthy people. That last part mattered. Many drugs help impaired patients. Few do anything measurable for a healthy brain.

UCB recognized what it had. The company launched this new 'drug' as 'Nootropil' in Europe in the early 1970's. The commercial name and the new scientific category landed at roughly the same moment.

Piracetam also kicked off a whole family of related compounds. Since the discovery of Piracetam, dozens of piracetam like drugs (nootropics) have been created in the racetam-class of compounds. And all have a pyrrolidone nucleus at their core.

The Nootropic Definition: Giurgea's Five Criteria

Giurgea did something most discoverers never bother to do. He set the bar for everyone who came after him, publishing five conditions a compound had to meet to qualify.

Per Wikipedia's summary of his work, Giurgea stated that nootropic drugs should have these characteristics:

1. They should enhance learning and memory.
2. They should enhance the resistance of learned behaviors or memories to conditions which tend to disrupt them (e.g. electroconvulsive shock, hypoxia).
3. They should protect the brain against various physical or chemical injuries.
4. They should increase the efficacy of the tonic cortical control mechanisms.
5. They should lack the usual pharmacology of other psychotropic drugs (e.g. sedation, motor stimulation) and possess few adverse effects and low toxicity.

Read that fifth point again. It is the one the modern supplement aisle quietly ignores.

The Criterion Most Products Skip

The fifth rule is the strictest, and it is the heart of the whole concept. A real nootropic, in Giurgea's framing, has to help without acting like a stimulant or a sedative, and it has to do so safely.

That single rule disqualifies a lot of what gets marketed today. A jittery pre-workout that spikes you and drops you is not nootropic by this standard, because it carries the side effects he wanted to exclude. The original bar was high benefit paired with low harm.

It is worth being honest about one thing here. There is no globally accepted or clinical definition of a nootropic. Giurgea's five criteria remain the closest thing the field has to a founding charter, but regulators never adopted them, which is part of why the word now gets stretched to cover almost anything.

How the Concept Spread

Where did nootropics come from after 1972? They left the lab and entered culture, fast.

Giurgea kept refining the idea for decades, including a 1982 paper revisiting the concept ten years on. His framework gave researchers a shared vocabulary for studying compounds aimed at cognition rather than illness.

The clinical side grew too. Piracetam and its relatives have been studied for conditions ranging from age-related cognitive decline to stroke recovery, with mixed and often debated results. The cultural side grew faster than the evidence, feeding decades of interest in "smart drugs" and cognitive optimization.

A Quick Timeline

Conclusion

Nootropics were not stumbled into by a marketing team. They were named and defined by one scientist, Corneliu Giurgea, who built a category around a single demanding idea: a compound should improve the mind without the baggage of sedation, overstimulation, or toxicity.

Piracetam came first, by accident, when a failed motion-sickness drug turned out to sharpen healthy brains. The word came second, in 1972, along with five rules that set a high standard most modern products never meet. More than fifty years later, the founder's real contribution was not the molecule. It was the standard.

Frequently Asked Questions

Who invented nootropics?

Corneliu Giurgea, a Romanian-born pharmacologist working at the Belgian company UCB, invented the concept of nootropics. He coined the term in 1972 and defined the five criteria a compound must meet to qualify. He also synthesized the first nootropic, piracetam, around 1964. So Giurgea is responsible for both the original molecule and the framework that named and shaped the entire field.

What was the first nootropic?

Piracetam was the first nootropic. Giurgea synthesized it at UCB Pharma in roughly 1964, originally hoping it would calm motion sickness. It failed at that and instead appeared to support learning and memory, even in healthy people. UCB later sold it in Europe under the name Nootropil. It remains the foundational member of the racetam family of compounds.

What does the word "nootropic" mean?

The word is built from Greek roots. "Noo" refers to the mind, and the "trop" element refers to turning or directing toward something. Giurgea's intent was a substance that acts toward the mind specifically, rather than one that sedates, stimulates, or alters mood. Translations differ slightly, with some sources saying "toward the mind" and others "to bend the mind," but the meaning is consistent.

What are Giurgea's five criteria for a nootropic?

A true nootropic should enhance learning and memory, protect those memories against disruption, shield the brain from physical or chemical injury, improve the brain's cortical control mechanisms, and, critically, avoid the usual side effects of psychotropic drugs while staying low in toxicity. That last requirement, few side effects and low toxicity, is the strictest and the most often ignored by modern products.

Is there an official definition of a nootropic today?

No. There is no globally accepted or clinical definition of a nootropic. Giurgea's 1972 criteria remain the most respected reference point, but regulators never formally adopted them. That gap is why the word now gets applied loosely to supplements, prescription drugs, and stimulant blends that would not pass his original five-part test.

Where did nootropics come from?

They came from a UCB laboratory in Belgium during the 1960s. Giurgea trained in the physiology tradition of Ivan Pavlov, synthesized piracetam, and recognized that it improved cognition rather than calming patients. He then built a scientific category around that observation in 1972. The idea spread from clinical research into popular culture over the following decades.

The Standard Giurgea Set, Now in a Pouch

Giurgea's most useful idea was not piracetam. It was his fifth rule: real cognitive support should help without the crash, the jitters, or the toxicity that come with ordinary stimulants. That is a high bar, and it is the one worth holding any modern product to.

Roon is built around that same logic. Each sublingual pouch carries four researched ingredients, 80 mg caffeine, 60 mg L-theanine, 25 mg methylliberine (Dynamine), and 5 mg theacrine (TeaCrine), chosen to support 6 to 8 hours of steady focus with no jitters, no crash, and no tolerance buildup. The format works in 5 to 10 minutes because it absorbs under the tongue.

To be clear, Roon is not piracetam and not a medical treatment for anything. It is a daily focus tool measured against Giurgea's original standard: meaningful benefit, minimal downside. If that is the trade-off you want, it is worth a try.

Written by Roon Team